Healthcare / Medical DevicesStockholm
$0.16
-0.00 (-1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-79.0M · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$682M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-122.5%
↓Gross Margin
74.8%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.9%
FCF CAGR
—
FCF margin
-459.3%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.5M · net income $-58.2M · FCF $-62.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.5M | $13.5M | $13.0M | $10.3M | $6.6M |
| Net Income | $-58.2M | $-58.2M | $-76.0M | $-94.8M | $-77.3M |
| EBITDA | $-49.3M | $-49.3M | $-66.0M | $-85.0M | $-69.1M |
| EPS | -0.06 | -0.06 | -0.16 | -0.20 | -0.22 |
| Gross Margin | 74.8% | 74.8% | 82.3% | 121.4% | 207.6% |
| Operating Margin | -428.1% | -428.1% | -593.8% | -939.8% | -1166.7% |
| Net Margin | -431.1% | -431.1% | -584.6% | -920.4% | -1171.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.03 | 0.06 | 0.04 |
| Current Ratio | 1.70 | 1.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-62.0M | $-62.0M | $-79.0M | $-94.3M | $-80.8M |
| Returns | |||||
| ROE | -122.5% | -122.5% | -90.7% | -112.2% | -43.5% |
| Valuation | |||||
| P/B | 3.23 | 3.23 | 0.74 | 4.60 | 4.64 |
| Growth & Yield | |||||
| Revenue Growth | 3.8% | 3.8% | 26.2% | 56.1% | — |
| EPS Growth | 62.5% | 62.5% | 21.7% | 8.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+38.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.06
Residual
+38.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.